Search clinical trials for: E200K mutation

Total 3272 results

Mario Negri Institute for Pharmacological Research

Recruiting

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy (aHUS-iPSC-EC)

Atypical Hemolytic Uremic Syndrome

Italy
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA)

Non-Small Cell Lung Cancer (NSCLC)

Korea, Republic of, Malaysia, Taiwan, Thailand, Hong Kong, Singapore, Canada
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China
Mayo Clinic
AbbVie; Cedars-Sinai Medical Center; Ironwood Pharmaceuticals, Inc.

Not yet recruiting

A Study of Virtual Reality and Linaclotide for IBS-C (IBSC-VR)

Irritable Bowel Syndrome With Constipation

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Australia, Brazil, China, United Kingdom, Israel, Belgium, Netherlands, Argentina, Spain, Taiwan, Canada, Italy, Poland, Turkey, Sweden, Switzerland
Regeneron Pharmaceuticals

Recruiting

A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations (CHORD)

Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Spain, United Kingdom, United States
Black Diamond Therapeutics, Inc.

Recruiting

A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Melanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditions

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations (DETERMINE)

Colorectal Neoplasms | Ovarian Neoplasms | Solid Tumor | Gallbladder Neoplasms | Prostatic Neoplasm | Pancreatic Neoplasm | Lung Neoplasm | Haematological Malignancy | Urinary Bladder Neoplasm | Skin Neoplasm | Salivary Gland Neoplasm

United Kingdom
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. (TEMPLE-2)

Non Small Cell Lung Cancer

Italy
Yonsei University

Not yet recruiting

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS)

Non-small Cell Lung Cancer

Korea, Republic of
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
National Cancer Centre, Singapore
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

NSCLC

Singapore
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. (DETERMINE)

Glioma | Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Brain Neoplasms | Solid Tumor | Malignant Neoplasm | Malignancy | Haematological Malignancy

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)

Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Neoplasms by Site | Renal Cell Carcinoma | Cancer | Solid Tumor | Anaplastic Large Cell Lymphoma | Neuroblastoma | Malignant Neoplasm | Haematological Malignancy

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE)

Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Colorectal Neoplasms | Endometrial Neoplasms | Malignant Neoplasm | Malignancy

United Kingdom
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES

Ovarian Cancer | Ultrasound Therapy; Complications | BRCA Mutation

Italy
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
Sun Yat-sen University

Recruiting

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Brain Metastases | Radiotherapy | EGFR Activating Mutation

China
Scorpion Therapeutics, Inc.

Recruiting

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Breast Cancer | Gynecologic Cancer | HNSCC | Solid Tumors, Adult

United States, Spain, France, Italy
GenEros Biopharma Hangzhou Ltd

Recruiting

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Advanced Solid Tumors

China
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE)

Glioma | Melanoma | Carcinoma, Non-Small-Cell Lung | Multiple Myeloma | Colorectal Neoplasms | Ovarian Neoplasms | Solid Tumor | Thyroid Cancer, Papillary | Thyroid Carcinoma, Anaplastic | Laryngeal Neoplasms | Erdheim-Chester Disease | Haematological Malignancy

United Kingdom
Istituto Auxologico Italiano

Recruiting

Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY (PTC-ARRAY)

Papillary Thyroid Cancer

Italy
Taiho Oncology, Inc.

Recruiting

A Study of TAS3351 in NSCLC Patients With EGFRmt (TAS3351)

Non-Small Cell Lung Cancer

United States, France, Italy, Korea, Republic of, Japan, Spain, Germany, Netherlands, United Kingdom
National Neuroscience Institute
Singapore General Hospital

Recruiting

Genotype Guided Antiplatelet Therapy In Ischemic Stroke

Ischemic Stroke | Transient Ischemic Attack

Singapore
Ying Lin

Recruiting

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation (IMPARP)

Her-2 Negative Breast Cancer | HRR Gene Mutation

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Advance Non-small Cell Lung Cancer

Spain, Italy, Greece
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Non-small Cell Lung Cancer

China
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Recruiting

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Identification of Clinically Significant Markers of ATTRv in Pre-symptomatic Mutation Carriers.

Amyloidosis

Italy
Dermatologic Cooperative Oncology Group

Recruiting

Multicenter Tissue Registry in Melanoma (TRIM)

Metastatic Melanoma

Germany
SparingVision

Recruiting

Promising ROd-cone DYstrophy Gene therapY (PRODYGY)

Retinitis Pigmentosa

United States, France
RemeGen Co., Ltd.

Not yet recruiting

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Non-small Cell Lung Cancer

China
Masonic Cancer Center, University of Minnesota

Recruiting

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Acute Leukemia | Neurofibromatosis 1 | Hematologic Malignancy | Myelodysplasia | Minimal Residual Disease | Chromosome Abnormality | Monosomy 7 | Remission | Somatic Mutation | Cytogenetic Abnormality | TP53 | Fetal Hemoglobin | Intrachromosomal Amplification of Chromosome... and other conditions

United States
Kura Oncology, Inc.

Recruiting

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Myeloid Sarcoma | Acute Myeloid Leukemia Recurrent | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia | Refractory AML | NPM1 Mutation | Mixed Lineage Leukemia Gene Mutation | AML With Mutated NPM1 | KMT2Ar

United States
Mirati Therapeutics Inc.

Recruiting

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Pancreatic Adenocarcinoma | Solid Tumor | Advanced Solid Tumor | Non-small Cell Lung Cancer | Colo-rectal Cancer

United States
Deciphera Pharmaceuticals LLC

Recruiting

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)

GIST

United States, Korea, Republic of, Spain, France, Taiwan, Italy, Australia, Canada, Germany, United Kingdom, Netherlands, Brazil, Chile, Poland
Sun Yat-sen University

Recruiting

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Colorectal Cancer Metastatic

China
Karolinska University Hospital
Sahlgrenska University Hospital, Sweden

Recruiting

Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) (A-SAB)

Non-small Cell Lung Cancer | ALK Gene Mutation | Radiotherapy Side Effect

Sweden
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
Instituto Nacional de Cancerologia de Mexico

Recruiting

Alectinib Pharmacokinetic in Patients With NSCLC

ALK Gene Mutation | Non-small Cell Lung Cancer Stage IIIB

Mexico
Federation Francophone de Cancerologie Digestive
Merck Sharp & Dohme LLC; Pierre Fabre Laboratories

Recruiting

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF)

Colorectal Cancer | BRAF V600E Mutation Positive

France
Novartis Pharmaceuticals

Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma

Korea, Republic of
San Raffaele University
Unita' di Gastroenterologia - Policlinico Universitario di Bari; Unita' di... and other collaborators

Recruiting

Videocapsule Endoscopy in Lynch Syndrome

Lynch Syndrome | MLH1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | Lynch Syndrome II | Small Bowel Adenocarcinoma | Lynch Syndrome I

Italy
Samara State Medical University

Recruiting

Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML

Endothelial Dysfunction | Cardiotoxicity | Acute Myeloid Leukemia, Adult

Russian Federation
Shanghai Chest Hospital

Recruiting

Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations

NSCLC | NSCLC Stage IV | NSCLC, Recurrent

China
Nir Peled

Not yet recruiting

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

Non Small Cell Lung Cancer | EGFR Gene Mutation | Immune Checkpoint Inhibitor

Israel
Labcorp Drug Development Inc

Recruiting

PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine (PREFER)

Melanoma | Soft Tissue Sarcoma | Stomach Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Rhabdomyosarcoma | Uterine Cancer

United States
Sermonix Pharmaceuticals Inc.

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

Metastatic Breast Cancer

United States, France, Belgium, Spain, Israel, Taiwan, United Kingdom, Korea, Republic of, Italy, Australia, Germany, Canada, Czechia, Hungary, Poland, Romania, Singapore, Turkey
University of California, San Francisco
GlaxoSmithKline

Recruiting

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Metastatic Solid Tumor | BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation

United States
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Lynch Syndrome | Pancreatic Ductal Adenocarcinoma | Chronic Pancreatitis | Pancreatic Cyst | Ataxia Telangiectasia | FAP | Peutz-Jeghers Syndrome | PALB2 Gene Mutation | BRCA Mutation | Fatty Pancreas | Genetic Pancreatic Cancer | Genetic Pancreatitis | Familial Atypical Multiple Mole-Melanoma

United States

Search clinical trials for: E200K mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations